SCYNEXIS, Inc. (SCYX), a biotechnology company specializing in treatments for drug-resistant infections, has initiated dosing in its Phase 1 clinical trial for SCY-247, a second-generation antifungal candidate.
SCY-247 is designed to treat severe invasive fungal infections, addressing the growing concern of antimicrobial resistance (AMR) in systemic fungal diseases.
The Phase 1 trial is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of oral SCY-247 in approximately 100 healthy subjects.
The trial will evaluate both single and multiple ascending doses. The primary endpoint is safety and tolerability, while secondary endpoints focus on pharmacokinetics.
SCY-247, part of SCYNEXIS' triterpenoid antifungal platform, has shown broad-spectrum activity in preclinical studies against both drug-sensitive and multidrug-resistant fungal pathogens. It also demonstrates activity against many fungi on the World Health Organization's (WHO) fungal priority pathogen list.
SCYNEXIS anticipates that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Fast Track and Qualified Infectious Disease Product (QIDP) designations, expediting its development.
Dr. David Angulo, CEO of SCYNEXIS, highlighted the urgency for new antifungal therapies, given the high mortality rates of invasive fungal infections and increasing drug resistance. He emphasized that SCY-247 represents a promising new treatment that could address critical gaps in the antifungal space.
In addition to advancing SCY-247, SCYNEXIS has made significant strides in the antifungal market.
The company's antifungal medication BREXAFEMME (ibrexafungerp tablets), approved by the FDA for patients with vulvovaginal candidiasis, has been licensed to GSK.
SCYX closed Wednesday's (Dec. 18, 2024) trading at $1.01, down 9.01%.
For comments and feedback: editorial@rttnews.com